Retatrutide · 5 mg
Supplier certificate pending
Incretin and metabolic
Retatrutide
Lyophilized Retatrutide for laboratory research. Supplied unreconstituted.
Also searched as: LY3437943, reta, ret
20 mg
€74.99
- Amount
- 5 mg, 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg
- CAS
- 2381089-83-2
- Catalog code
- LY3437943
- Storage
- −20 °C · dry · dark
Help fund independent testing
- Retatrutide · 5 mgIn the current test vote: #64
- Retatrutide · 10 mgIn the current test vote: #61
- Retatrutide · 20 mgIn the current test vote: #62
- Retatrutide · 30 mgIn the current test vote: #1
- Retatrutide · 40 mgIn the current test vote: #63
- Retatrutide · 50 mgIn the current test vote: #65
- Retatrutide · 60 mgIn the current test vote: #66
About this material
Retatrutide is supplied by Rierink Compounds as a laboratory research material. Made in Europe. It sits with the peptides studied in laboratory research on incretin and metabolic signaling. The material is a lyophilized powder and is supplied unreconstituted. The companion reagent listed for it is BAC water. Store at −20 °C, dry and protected from light. For laboratory research use only. Not a medicine. Not for human or veterinary use. Rierink does not publish reconstitution volumes, dosing, or administration guidance.
Research context
Retatrutide (catalog code LY3437943, CAS 2381089-83-2) is an investigational peptide described in published research as a receptor agonist at GIP, GLP-1, and glucagon. Phase 2 metabolic studies of that investigational material have reported changes in body weight and glycaemic measures in participants. Rierink supplies only the lyophilized research powder. Those trials are not a protocol for this vial. Published studies describe a research material and a study design. They are not a protocol for this vial, not a dose, and not a permission for human or veterinary use.
Recommended reagent
This is the laboratory reagent listed with this lyophilized material.
Certificates
These certificates come from our supplier and relate to the supplier's batches. They are not Rierink's own independent tests of the exact vial you receive. Every Rierink vial carries our own internal lot number, and independent testing of our own lots is underway; results will be published per lot. We welcome independent testing: any customer or lab is free to test our products, and we're happy to share results sent to us.
Retatrutide · 10 mg
Supplier certificate pending
Retatrutide · 20 mg
- Compound
- Retatrutide
- Amount
- 20 mg
- Task number
- 223860
- Verification key
- 2JXK17H8SDHQ
- Purity
- 99.865%
- Measured content
- 19.86 mg
Verified on janoshik.com/verification as a genuine Janoshik report for the sample tested; not a test of a Rierink lot.
Retatrutide · 30 mg
Supplier certificate pending
Retatrutide · 40 mg
Supplier certificate pending
Retatrutide · 50 mg
Supplier certificate pending
Retatrutide · 60 mg
- Compound
- Retatrutide
- Amount
- 60 mg
- Purity
- 99.87%
- Measured content
- 60.73 mg
Supplier-issued; cannot be independently verified.
Research briefings
- Favorable and unfavorable findings on TirzepatideClinical trials and meta-analyses of tirzepatide report substantial mean weight loss (15–21%), glycemic improvements, cardiometabolic benefits, heart failure event reduction, and superior weight loss versus semaglutide. These are accompanie
- Favorable and unfavorable findings on RetatrutideClinical trials of retatrutide (LY3437943), a GIP/GLP-1/glucagon triple receptor agonist, report substantial mean weight loss (18-25% at 80 weeks in phase 3 TRIUMPH studies), glycemic improvements, cardiometabolic benefits, and gains in knee osteoarthritis pain and obstructive sleep apnea. However, dose-dependent gastrointestinal adverse events, dysesthesia, increased heart rate, and higher discontinuation rates are consistently reported alongside inconclusive cardiovascular outcomes and data gaps on long-term safety.
- Retatrutide Triple Agonism: Preclinical Pharmacology and TRIUMPH Clinical OutcomesIndexed preclinical and clinical papers describe retatrutide (LY3437943) as a unimolecular triple agonist of GIP, GLP-1, and glucagon receptors studied for weight loss, glycemic control, energy expenditure, and cardiometabolic readouts. Pha
Trustpilot
A small laboratory is built one honest sentence at a time.
We're new on Trustpilot and don't have any reviews yet. Be one of the first to share your experience.
We are still the company that picks up the phone. The next researcher finds us because someone wrote down what actually happened: the lot that matched the label, the parcel that arrived late, the reply that took a day too long. That public record is how a young lab earns a name.
Write the first review